Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Conditions
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Trial Timeline
Jun 22, 2021 → May 30, 2029
NCT ID
NCT04802759About Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab
Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab is a phase 1/2 stage product being developed by Roche for Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04802759. Target conditions include Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04802759 | Phase 1/2 | Recruiting |
Competing Products
10 competing products in Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin Mesylate | Eisai | Pre-clinical | 23 |
| Premetrexed (Alimta) + Carboplatin | Eli Lilly | Phase 1 | 33 |
| Fulvestrant + Capivasertib + Placebo | AstraZeneca | Phase 3 | 77 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Tomudex | AstraZeneca | Phase 2 | 52 |
| Cisplatin + Gemcitabine + Selumetinib | AstraZeneca | Phase 1 | 33 |
| Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | AstraZeneca | Phase 3 | 77 |
| Drug (including placebo) | Merck | Phase 1 | 33 |
| BEZ235 + Paclitaxel | Novartis | Phase 1/2 | 41 |
| dacomitinib hydrate | Pfizer | Pre-clinical | 22 |